Hormone replacement therapy restores hormones your body has stopped making in sufficient quantities, and the effects ripple through nearly every organ system. In menopausal women, the core action is replacing estradiol and, when needed, progesterone; in gender-affirming care, the goal is shifting the dominant sex-hormone profile toward the one that matches a person’s gender identity. What makes HRT fascinating is how far-reaching those hormones are: they don’t just quiet hot flashes. They influence how your bones rebuild, how your blood vessels relax, how your brain fuels itself, and even how your gut bacteria handle hormone recycling.
The Hormonal Drop That Starts It All
Before understanding what HRT adds back, it helps to know what disappears. At menopause, the ovaries run out of viable follicles, and the two hormones they produced in abundance, estradiol and progesterone, fall dramatically.1Experimental Gerontology. Changes of ovarian hormonal function with aging The brain detects this absence through a feedback loop: with less estradiol circulating, the pituitary gland ramps up follicle-stimulating hormone (FSH) in an attempt to coax the ovaries into action. FSH levels begin climbing roughly six years before the final menstrual period and eventually reach a plateau about fourteen times higher than those seen in men.2PubMed Central. Follicle-stimulating hormone: More than a marker for menopause That surge never succeeds, because the follicles are gone. The result is a body that was built to run on estrogen and progesterone now operating without meaningful levels of either.
What Estrogen Actually Does Once It Enters a Cell
When you take HRT, the estradiol you swallow, absorb through your skin, or apply vaginally enters the bloodstream and reaches cells throughout the body. Once inside a cell, estradiol binds to estrogen receptors. Two nuclear versions of these receptors, called ERα and ERβ, sit inside cells in tissues ranging from bone to brain to blood vessels. A third type, found on cell membranes, triggers faster signaling events that don’t require the hormone to enter the nucleus at all.3PubMed Central. Estrogen receptor signaling mechanisms
The nuclear receptors work by attaching to specific stretches of DNA and switching genes on or off. This is a slower process, unfolding over hours, and it’s responsible for many of the lasting tissue changes HRT produces: thicker vaginal walls, denser bone, more collagen in skin. The membrane receptor triggers rapid chemical cascades inside the cell within minutes, affecting things like blood-vessel tone and neuron firing. HRT taps both of these pathways simultaneously, which is why its effects feel both immediate (fewer flashes within days to weeks) and gradual (bone density improvements over months to years).
How HRT Stops Hot Flashes
Hot flashes are the symptom most people associate with menopause, and the mechanism behind them has only been mapped in detail relatively recently. The culprits are a cluster of neurons deep in the hypothalamus that produce three signaling molecules: kisspeptin, neurokinin B, and dynorphin. Researchers call them KNDy neurons. In premenopausal life, estrogen keeps these neurons in check. When estrogen disappears, KNDy neurons become hyperactive.4PubMed Central. Modulation of body temperature and LH secretion by hypothalamic KNDy (kisspeptin, neurokinin B and dynorphin) neurons
These neurons project to the brain’s thermostat, the preoptic area of the hypothalamus, and when they fire in bursts, they release neurokinin B there. That triggers the brain to launch a heat-dissipation response: blood vessels near the skin surface dilate, sweat glands activate, and your core temperature drops. You experience this as a hot flash followed by a chill. Animal studies have shown that artificially activating these neurons produces flushing and temperature drops even in males, and that blocking the neurokinin B receptor in the preoptic area abolishes the response entirely.5PubMed Central. A Neural Circuit Underlying the Generation of Hot Flushes When KNDy neurons were destroyed in animal models, the usual estrogen-driven regulation of skin blood-vessel dilation was disrupted, confirming that these neurons are a critical relay between estrogen and your body’s thermostat.6PubMed Central. Role for kisspeptin/neurokinin B/dynorphin (KNDy) neurons in cutaneous vasodilatation and the estrogen modulation of body temperature
HRT quiets this circuit by restoring estrogen’s inhibitory effect on KNDy neurons. The neurons calm down, the inappropriate heat-dump signals stop, and flashes subside. This is also why a newer class of non-hormonal drugs designed to block the neurokinin B receptor can reduce flashes without estrogen, though they address only this one circuit rather than the body-wide effects HRT provides.
Bone Turnover and the RANKL Connection
Your skeleton is not a static structure. Specialized cells called osteoclasts constantly dissolve small pockets of old bone, while osteoblasts lay down fresh bone to fill those pockets. Estrogen keeps this demolition crew on a short leash. It does so partly by suppressing a protein called RANKL, which is the primary signal that tells osteoclast precursors to mature into active bone-dissolving cells. In estrogen-deficient states, bone-lining cells ramp up RANKL production, and osteoclast activity surges.7PubMed Central. Estrogen Regulates Bone Turnover by Targeting RANKL Expression in Bone Lining Cells Estrogen also directly interferes with the ability of precursor cells to become osteoclasts in the first place, acting through a separate mechanism that doesn’t depend on bone-lining cells at all.8PubMed. Estrogens suppress RANK ligand-induced osteoclast differentiation via a stromal cell independent mechanism involving c-Jun repression
When you start HRT, estradiol re-enters bone tissue, RANKL expression drops back down, osteoclast formation slows, and the balance between bone breakdown and bone building tips back toward preservation. This is why HRT has a measurable effect on bone density and fracture risk, though the benefit depends on continued use: once you stop, the estrogen brake on RANKL lifts and bone loss accelerates again.
Blood Vessels and Nitric Oxide
Estrogen has a direct relationship with the inner lining of blood vessels, the endothelium. One of its key effects is boosting production of nitric oxide, a small molecule that relaxes blood vessel walls and improves blood flow. Estradiol increases both the amount of the enzyme that makes nitric oxide (eNOS) and the degree to which that enzyme is active.9Endocrine Reviews. Estrogen Modulation of Endothelial Nitric Oxide Synthase This happens through both of estrogen’s signaling modes: the slower gene-expression pathway increases total eNOS protein over time, while the faster membrane-receptor pathway activates existing eNOS molecules almost immediately.10PubMed. Regulation of endothelial nitric oxide synthase and high-density lipoprotein quality by estradiol in cardiovascular pathology
In lab studies, estrogen treatment produced measurably higher eNOS activity in cerebral blood vessels, and blocking the estrogen receptor with antagonist drugs completely prevented that increase.11PubMed. Estrogen increases endothelial nitric oxide synthase via estrogen receptors in rat cerebral blood vessels Nitric oxide doesn’t just relax vessels. It also discourages the buildup of plaques on artery walls, making it part of estrogen’s broader protective effect on the cardiovascular system. This is one reason younger, recently menopausal women appear to derive cardiovascular benefit from HRT, and why losing estrogen at menopause correlates with stiffer arteries and rising blood pressure.
When You Start Matters for Your Heart
The cardiovascular story of HRT has been one of the most confusing in modern medicine. In 2002, a large trial was halted early after finding that a specific combination of conjugated estrogens and a synthetic progestin increased the risk of heart disease, stroke, and blood clots.12JAMA. New Analysis of Women’s Health Initiative Data Aims to “Clear the Air” Over Menopausal Hormone Therapy That finding drove millions of women off HRT essentially overnight. In the years since, reanalysis of the data and new studies have revealed a more complicated picture: the trial’s average participant was in her mid-sixties and more than a decade past menopause, and limitations in the study design contributed to an overly broad interpretation of risk.13PubMed. Reappraising 21 years of the WHI study: Putting the findings in context for clinical practice
The current understanding is captured in what researchers call the “timing hypothesis”: HRT started within ten years of menopause onset, or before age 60, may reduce coronary heart disease risk and overall mortality, while starting later may increase cardiovascular risk.14PubMed Central. The impact of hormone replacement therapy on cardiovascular health in postmenopausal women: a narrative review Accumulated data support this window of opportunity, with maximum benefit seen when therapy is continued for six years or more.15PubMed Central. The timing hypothesis for coronary heart disease prevention with hormone therapy: past, present and future in perspective The logic connects back to the nitric oxide pathway: estrogen can maintain healthy, flexible arteries, but once significant plaque has already built up in older vessels, adding estrogen may destabilize those plaques rather than protect them. Healthy endothelium responds to estrogen positively. Damaged endothelium may not.
Why the Delivery Route Changes the Risk Profile
Whether you swallow an estrogen pill or absorb it through a skin patch makes a real physiological difference. Oral estrogen passes through the liver before entering general circulation, a process called first-pass metabolism. That hepatic transit stimulates the liver to produce more clotting factors and inflammatory proteins. Studies have shown that oral HRT increases thrombin generation and induces a resistance to one of the body’s natural anti-clotting mechanisms, activated protein C.16PubMed. Risk of venous thrombosis with oral versus transdermal estrogen therapy among postmenopausal women Oral users also showed higher levels of clotting factor IX and C-reactive protein, an inflammatory marker, while transdermal users did not show these changes.17Thrombosis and Haemostasis. Different Effects of Oral and Transdermal Hormone Replacement Therapies on Factor IX, APC Resistance, t-PA, PAI and C-reactive Protein
Transdermal estrogen, delivered via patch, gel, or spray, enters the bloodstream through the skin and bypasses the liver entirely. The estradiol reaches target tissues at comparable concentrations, but without provoking the hepatic clotting cascade. This is why many clinicians now prefer transdermal delivery, particularly for women who are overweight, have a history of blood clots, or carry other vascular risk factors. The estrogen molecule itself is the same; the difference is entirely about what the liver does or doesn’t see.
What Progesterone Does and Why the Type Matters
If you still have a uterus, HRT almost always includes a progestogen alongside estrogen. The reason is straightforward: estrogen on its own stimulates the uterine lining to grow, and unopposed growth over time raises the risk of endometrial cancer. Adding a progestogen triggers the lining to shed or stabilize, preventing that buildup.18PubMed Central. Estradiol and Micronized Progesterone: A Narrative Review About Their Use as Hormone Replacement Therapy
But not all progestogens behave the same way in the rest of the body. Synthetic progestins, while effective at protecting the endometrium, have varied and sometimes unfavorable effects on metabolism, cardiovascular markers, and breast tissue. Micronized progesterone, which is chemically identical to the progesterone your ovaries once made, tends to produce more physiological effects across those systems.18PubMed Central. Estradiol and Micronized Progesterone: A Narrative Review About Their Use as Hormone Replacement Therapy A systematic review and meta-analysis found that using progesterone rather than synthetic progestins alongside estrogen was associated with about a third lower breast cancer risk.19PubMed Central. Progesterone vs. synthetic progestins and the risk of breast cancer: a systematic review and meta-analysis Ongoing trials are comparing these compounds head-to-head on outcomes like mammographic breast density and endometrial changes, to refine the picture further.20PubMed Central. Breast and endometrial safety of micronised progesterone versus norethisterone acetate in menopausal hormone therapy (PROBES)
Your Brain’s Energy Supply
Estrogen plays a less-publicized but significant role in how the brain powers itself. Neurons are voracious energy consumers, and estrogen regulates multiple steps in how they obtain and use fuel: glucose transport into brain cells, the conversion of glucose into usable energy, and the function of mitochondria, the structures inside cells where most energy production happens.21PubMed Central. Estrogen: a master regulator of bioenergetic systems in the brain and body Research in hippocampal and cortical neurons has shown that estrogen-driven signaling converges on mitochondria to sustain energy production, maintain calcium balance, and protect against free-radical damage.22PubMed Central. Estrogen regulation of glucose metabolism and mitochondrial function: therapeutic implications for prevention of Alzheimer’s disease
This matters because many of the cognitive complaints women report around menopause, brain fog, difficulty concentrating, and memory lapses, may partly reflect a brain that has lost its metabolic regulator. The evidence suggests that estrogen intervention in a still-healthy brain can help sustain neural defenses, while waiting until neurodegeneration has already set in offers less benefit.22PubMed Central. Estrogen regulation of glucose metabolism and mitochondrial function: therapeutic implications for prevention of Alzheimer’s disease The timing theme echoes the cardiovascular story: early intervention appears to preserve function that late intervention cannot restore.
Vaginal and Urinary Tract Effects
The tissues of the vagina, vulva, and lower urinary tract are especially rich in estrogen receptors, and they’re often the first to show the effects of estrogen loss. Walls thin, natural lubrication drops, the vaginal pH rises, and the population of protective lactobacilli dwindles. These changes can cause dryness, irritation, pain with intercourse, and a higher frequency of urinary tract infections.
Low-dose vaginal estrogen, applied directly as a cream, tablet, or ring, reverses many of these changes locally. It restores the vaginal lining, brings blood flow back to the tissue, lowers pH, repopulates lactobacilli, and reduces recurrent UTIs.23American Journal of Obstetrics & Gynecology. Genitourinary syndrome of menopause: an overview of clinical manifestations, pathophysiology, etiology, evaluation, and management Because the dose is low and the absorption is primarily local, vaginal estrogen carries far less systemic risk than oral or transdermal forms, and many guidelines consider it safe even for women with contraindications to systemic HRT.
Metabolic and Body Composition Shifts
Estrogen influences how the body handles insulin and where it stores fat. Before menopause, women tend to carry fat subcutaneously on hips and thighs; after menopause, fat distribution shifts toward the visceral pattern more typical of male bodies, clustering around internal organs in the abdomen. This visceral fat is metabolically active and contributes to insulin resistance. Evidence indicates that estrogen plays a protective role in insulin sensitivity, and that this protection fades at menopause but can be partially re-established with HRT.24PubMed Central. The Role of Estrogen in Insulin Resistance: A Review of Clinical and Preclinical Data While HRT is not prescribed for metabolic syndrome, restoring estrogen may shift the metabolic environment in a more favorable direction for women in early menopause.
Skin and Connective Tissue
Estrogen receptors exist in skin cells across multiple layers. Estrogen influences keratinocytes in the outer layer, fibroblasts that produce collagen and elastin in the deeper layer, and even melanocytes and hair follicles. Skin aging, including thinning, wrinkling, and reduced moisture, accelerates after menopause in a pattern that parallels estrogen decline rather than chronological aging alone. Administering estrogen can meaningfully delay these skin changes.25PubMed Central. Effect of estrogens on skin aging and the potential role of SERMs Collagen content in skin drops roughly in step with estrogen loss, and studies have consistently shown that women on HRT retain more collagen than age-matched women who are not. This isn’t a cosmetic side benefit so much as a reflection of how deeply estrogen is embedded in connective tissue maintenance throughout the body.
The Gut Microbiome and Estrogen Recycling
There’s a less obvious loop between HRT and your digestive system. Certain gut bacteria produce an enzyme called beta-glucuronidase, which reactivates estrogen molecules that the liver had deactivated and sent to the intestines for elimination. This collection of estrogen-processing bacteria is sometimes called the estrobolome. When gut microbial diversity is low, less beta-glucuronidase is produced, fewer estrogen molecules get reactivated, and circulating estrogen levels drop further.26PubMed. Estrogen-gut microbiome axis: Physiological and clinical implications
This means your gut health can affect how efficiently your body uses both its own estrogen and the estrogen supplied by HRT. A diverse, healthy microbiome recycles more estrogen back into circulation; a disrupted one lets more estrogen pass out of the body unused. It also raises the question of whether the gut changes that accompany menopause, including shifts in microbial diversity, partly compound the hormonal changes HRT is trying to address. Research on this axis is still in relatively early stages, but it suggests that gut health and hormone therapy aren’t separate conversations.
Gender-Affirming Hormone Therapy
HRT is not only a menopausal treatment. For transgender women, feminizing HRT involves estradiol to promote breast development, fat redistribution, and softer skin, usually combined with an antiandrogen to suppress testosterone. Different antiandrogens work by different mechanisms: some block testosterone’s receptor so the hormone is present but can’t act, while others suppress testosterone production at the source. A systematic review found that cyproterone acetate and leuprolide may be more effective than spironolactone at suppressing total testosterone levels, though because spironolactone blocks the androgen receptor directly, the difference in actual feminization may be less clear-cut clinically.27PubMed. A systematic review of antiandrogens and feminization in transgender women
For transgender men, masculinizing HRT consists of testosterone, delivered by injection, gel, or patch. Testosterone drives voice deepening, facial hair growth, muscle mass increases, and redistribution of body fat. One physiological effect that requires monitoring is a rise in red blood cell production. In one institutional study, hematocrit levels increased about 12% from baseline, and roughly a quarter of participants developed elevated red blood cell counts, though levels returned to normal with dose adjustment.28PubMed Central. Effects of testosterone treatment on transgender males: A single-institution study Testosterone also raised creatinine and uric acid levels while lowering fasting blood sugar, reflecting the broad metabolic fingerprint of androgen dominance. Regular blood work is a standard part of masculinizing HRT precisely because the body is adapting to an entirely different hormonal regime, and monitoring ensures that adaptation stays in a safe range.